TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$120.55 USD
+1.58 (1.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $120.51 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TMDX 120.55 +1.58(1.33%)
Will TMDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMDX
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?
Other News for TMDX
Morgan Stanley Raises Price Target for TMDX to $123 | TMDX Stock News
What TransMedics Just Taught Me About Trusting The Algorithm
TransMedics: Continued Strength Suggests Further Upside
TransMedics Group Inc (TMDX) Announces Inducement Grants to New Employees | TMDX stock news
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | TMDX Stock News